PROCRIT® is indicated for the treatment of anemia due to CKD, including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.
PROCRIT® has not been shown to improve quality of life, fatigue, or patient well-being.
PROCRIT® is not indicated for use:
When treating anemia in CKD patients not on dialysis
WARNINGS: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
Chronic Kidney Disease:
Expand the Important Safety Information at the bottom of the page to see the complete Boxed Warnings.
The adverse reactions with a reported incidence of ≥5% in PROCRIT®-treated patients and that occurred at a ≥1% higher frequency than in placebo-treated patients are shown in the table below:
Adverse reactions in patients with CKD not on dialysis1
ADVERSE REACTION | PROCRIT®-treated patients (n=131) | Placebo-treated patients (n=79) |
---|---|---|
Hypertension | 13.7% | 10.1% |
Arthralgia | 12.2% | 7.6% |